RBC Capital Reiterates Sector Perform on Regeneron Pharmaceuticals, Maintains $737 Price Target

Benzinga Newsdesk www.benzinga.com Positive 54.8%

Neg 0% Neu 0% Pos 54.8%

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and maintains $737 price target.